A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients

Smelson, David A.; Williams, John; Ziedonis, Douglas M.; Sussner, Bradley D.; Losonczy, Miklos F.; Engelhart, Charles; Kaune, Maureen

doi:10.1016/j.jsat.2004.03.009

Cited by 45 publications

(22 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19 These findings contrast, however, with 2 recent double-blind trials, one comparing olanzapine to a placebo 34 and the other comparing risperidol to a placebo, 35 which both failed to reduce substance use and craving among individuals with cocaine dependence, but without schizophrenia. It is possible that these 2 recent findings were due to the fact that individuals without schizophrenia may have a difficult time tolerating atypical neuroleptics.…”

Section: Discussionmentioning

confidence: 82%

The Efficacy of Olanzapine for Decreasing Cue-Elicited Craving in Individuals With Schizophrenia and Cocaine Dependence

Smelson¹,

Ziedonis²,

Williams³

et al. 2006

Journal of Clinical Psychopharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 82%

The Efficacy of Olanzapine for Decreasing Cue-Elicited Craving in Individuals With Schizophrenia and Cocaine Dependence

Smelson¹,

Ziedonis²,

Williams³

et al. 2006

Journal of Clinical Psychopharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…34 Cocaine-dependent schizophrenics have higher levels of craving in the early period of their treatment of cocaine dependence compared with nonschizophrenic addicts. 35 The pattern of cocaine use is more intermittent in schizophrenics than in the general population, which has been associated with variations in the severity of positive and negative symptoms. 36 The prevalence of amphetamine use varies according to studies, between 10% and 65%.…”

Section: Schizophrenia and Consumption Of Central Nervous System Stimmentioning

confidence: 99%

Protocols of Dual Diagnosis Intervention in Schizophrenia

Roncero

Barral

Grau-López

et al. 2011

Addictive Disorders &Amp; Their Treatment

View full text Add to dashboard Cite

show abstract

“…Several human laboratory studies found that the second-generation neuroleptics risperidone or olanzapine reduced cocaine-induced euphoria or cue-induced cocaine craving (Newton et al, 2001;Smelson et al, 1997Smelson et al, , 2002Smelson et al, , 2004Smelson et al, , 2006. One case-series of 21 outpatients on methadone maintenance for opiate dependence found that olanzapine (5-10 mg/d) substantially reduced cocaine use (Bano et al, 2001).…”

Section: Dopamine Antagonists and Partial Agonistsmentioning

confidence: 99%

New treatments for cocaine dependence: a focused review

Karila

Gorelick

Weinstein³

et al. 2007

Int. J. Neuropsychopharm.

167

116

View full text Add to dashboard Cite

Cocaine, already a significant drug problem in North and South America, has become a more prominent part of the European drug scene. Cocaine dependence has major somatic, psychological, psychiatric, socio-economic, and legal implications. No specific effective pharmacological treatment exists for cocaine dependence. Recent advances in neurobiology have identified various neuronal mechanisms implicated in cocaine addiction and suggested several promising pharmacological approaches. Data were obtained from Medline, EMBASE, and PsycINFO searches of English-language articles published between 1985 and June 2007 using the key words: cocaine, addiction, cocaine dependence, clinical trials, pharmacotherapy(ies) singly and in combination. Large well-controlled studies with appropriate statistical methods were preferred. Pharmacological agents such as GABA agents (topiramate, tiagabine, baclofen and vigabatrin) and agonist replacement agents (modafinil, disulfiram, methylphenidate) seem to be the most promising in treatment of cocaine dependence. The results from trials of first- and second-generation neuroleptics are largely negative. Aripiprazole, a partial dopaminergic agonist that may modulate the serotonergic system, shows some promise. Preliminary results of human studies with anti-cocaine vaccine, N-acetylcysteine, and ondansetron, are promising, as are several compounds in preclinical development. While no medication has received regulatory approval for the treatment of cocaine dependence, several medications marketed for other indications have shown efficacy in clinical trials. An anti-cocaine vaccine and several compounds in preclinical development have also shown promise. Findings from early clinical trials must be confirmed in larger, less selective patient populations.

show abstract

A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients

Cited by 45 publications

References 35 publications

The Efficacy of Olanzapine for Decreasing Cue-Elicited Craving in Individuals With Schizophrenia and Cocaine Dependence

The Efficacy of Olanzapine for Decreasing Cue-Elicited Craving in Individuals With Schizophrenia and Cocaine Dependence

Protocols of Dual Diagnosis Intervention in Schizophrenia

New treatments for cocaine dependence: a focused review

Contact Info

Product

Resources

About